The Food and Drug Administration has completed its review of Intra-Cellular Therapies Inc.'s (Nasdaq: ITCI) responses to the regulatory agency's requests for additional information and will allow the biopharmaceutical to proceed with its long term safety study of lumateperone. Shares of the biopharmaceutical leaped $3.12 to close at $14.39.
